Strategies for the Prevention of Recurrent Hepatitis B Virus Infection After Liver Transplantation

Vignan Manne, MD, Ruby M. Allen, and Sammy Saab, MD, MPH, AGAF

Abstract: Hepatitis B virus (HBV) infection is an international public health concern, and chronic infection can lead to the development of cirrhosis, liver failure, or hepatocellular carcinoma as well as the need for liver transplantation. The recurrence of HBV infection following liver transplantation was disproportionately high prior to the introduction of proper prophylactic treatment. Risk factors associated with the recurrence of HBV infection posttransplant include hepatitis B e antigen positivity, high levels of serum HBV DNA, and the presence of an antiviral drug–resistant strain prior to transplantation. The prevention of HBV recurrence began with the introduction of hepatitis B immunoglobulin (HBIG) in the early 1990s. Nucleos(t)ide analog (NA) antiviral drugs were next to be introduced and, in combination with HBIG, are considered to be extremely effective for the prevention of recurrence. Because of concerns with HBIG, whether HBIG can be used for a short time or discontinued altogether is under debate. All of the NA antiviral drugs have been proven to be effective against HBV, at least in the pretransplant setting, and can be used safely posttransplant. Further investigation is still needed to standardize treatment in the posttransplant setting.

Hepatitis B virus (HBV) infection is a serious worldwide public health concern. It is estimated that worldwide, almost 250 million persons have been infected and currently have chronic viral hepatitis due to HBV.1 Within the United States, the number of persons who are estimated to have chronic HBV infection is between 800,000 and 1.4 million, and the number of deaths per year associated with chronic liver disease due to HBV infection is estimated at approximately 3000.2

The clinical impact of HBV infection is primarily related to the high risk of associated hepatic complications. Patients with HBV infection are at increased risk for the development of cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Indeed, the HCC risk alone is thought to be almost 200 times greater in infected patients than in noninfected patients, and estimates of the risk of develop-
ment of other complications associated with HBV infection are between 15% and 40%.3,4

Despite advances in the antiviral therapies for HBV infection, liver transplantation remains the ultimate treatment for many patients with end-stage liver disease and HCC.5 The risk of reinfection posttransplantation without appropriate prophylaxis is disproportionately high and is associated with severe and rapidly progressive liver disease.6-8 Different combinations of drugs are currently used to prevent and treat patients with HBV infection who have undergone liver transplantation, but the optimal therapy that should be used is still currently under debate.9-12

Unlike hepatitis C virus infection, in which care revolves around treating recurrent disease, the goal in the management of recipients of liver transplants for the treatment of HBV infection is to prevent reinfection.

Risk Factors and the Clinical Course of Hepatitis B Virus Infection Following Liver Transplantation

Risk of Recurrence

The exact mechanism of how HBV infection recurrence occurs posttransplant is still not fully understood but is probably related to the required immunosuppression, particularly in relation to prednisone therapy. For instance, there is a glucocorticoid-responsive enhancer region within the HBV DNA genome.13-15 Another likely contributing factor could be the presence of extrahepatic HBV infection.16,17

The natural history and management of HBV infection recurrence in liver transplant recipients have evolved significantly over the past few decades. There has been a progressive incremental decrease in the risk of reinfection with the introduction of hepatitis B immunoglobulin (HBIG), oral antiviral agents, and a combination of HBIG and oral antiviral therapies. For instance, prior to the use of HBIG, the risk of reinfection with HBV was reported to be between 75% and 100% (Figure).5,18,19 Currently, the risk of reinfection is thought to be less than 10% with the use of combination HBIG and oral therapy.19,20

Multiple risk factors are associated with HBV infection recurrence in liver transplant recipients (Table 1).

Patients considered at high risk include those with cirrhosis who are hepatitis B e antigen–positive or –negative but with high levels of serum HBV DNA and patients who have an antiviral drug–resistant strain pretransplant.16,20-22

Other associated risk factors that can influence recurrence of HBV infection include no posttransplant prophylaxis or the presence of pretransplant HCC or posttransplant HCC recurrence.20,23-25

Clinical Course and Diagnosis

The reappearance of hepatitis B surface antigen (HBsAg) defines HBV recurrence.26,27 The results of a recent study demonstrated that patients with recurrence of HBV infection, as defined by HBsAg positivity, had varying degrees of hepatic inflammation but trended toward moderate to severe types of hepatic inflammation on biopsy.27 Techniques using polymerase chain reaction (PCR) have demonstrated the ability to detect HBV DNA even before the appearance of HBsAg or aberrations in liver function.28 Indeed, some patients can be seen to have detectable HBV DNA but still remain HBsAg-negative after follow-up periods as long as 10 years.29,30 Whether these patients will ultimately have recurrence of an active HBV infection remains to be seen, but the positive HBV DNA PCR with or without symptoms underscores the necessity of continuing therapy for HBV infection posttransplantation.
The clinical implications of HBV recurrence are significant if untreated because of the rapidity of deterioration associated with recurrence. Cirrhosis of the liver graft has been recorded within 1 to 2 years of recurrence post-transplant. 6-8,31

Prevention of Hepatitis B Virus Recurrence

The prevention of reinfection ideally begins in the pre-transplant period. All patients with decompensated cirrhosis and detectable HBV DNA, regardless of quantitative HBV DNA or liver function test abnormalities, should receive antiviral therapy. 16,21,22

Pretransplant

The choice of therapy pre-transplant is generally mono-therapy with an oral nucleos(t)ide analog (NA). First-line therapeutic agents are entecavir and tenofovir because of their high genetic barrier to drug resistance, potency, and low rate of discontinuation due to adverse effects. 32 The rate of resistance limits the utility of lamivudine and telbivudine (Tyzeka, Novartis), and low viral suppression rates prevent widespread use of adefovir.

Posttransplant

Immuno prophylaxis with HBIG and an oral NA should be started at the time of transplant. Strategies using HBIG vary according to the dose administered and may involve intravenous or intramuscular delivery. 33-36 An area of controversy is whether HBIG can eventually be discontinued. 20,28,37 A number of studies have addressed the issue of HBIG duration in liver transplant recipients. Limited use of HBIG, defined as 12 months or less of therapy, followed by a switch to an oral regimen of nucleotide/nucleoside combination appears to be effective in preventing recurrent HBV infection (Table 2). However, it is unclear whether HBIG is needed at all after liver transplantation in all patients who have received liver transplants for management of HBV infection.

There are several advantages to using an all-oral therapy over a strategy that still contains HBIG after a limited course of HBIG. One study conducted by Angus and colleagues compared the efficacy of dual therapy with 2 NAs, lamivudine and adefovir, with that of a combination of HBIG and lamivudine in patients who had at least 12 months of HBIG therapy, with the results showing similar efficacy between the 2 groups. 38 Another more recent study published by Teperman and colleagues also supports the theory that dual therapy with 2 NAs can be as effective as a combination of HBIG with 1 or 2 NAs after a limited period of HBIG use. 39 Many other studies using similar criteria to the ones noted above also support the conclusion that HBIG discontinuation is feasible. 7,37,38,40-44 Although a growing wealth of evidence supports the discontinuation of HBIG, most of the patients enrolled in the trials were generally considered to be at low risk, and HBIG was used for at least 12 months following transplant (considered the most vulnerable period) before it was discontinued. 38,39

Many institutions are now adopting HBIG-free regimens with oral NA therapy following transplantation if patients are thought to be at low risk of recurrent infection or are discontinuing HBIG after a period of time.

Table 2. Immunophrophylaxis for HBV Infection in Liver Transplant Recipients

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of Patients</th>
<th>Strategy</th>
<th>Oral Agents (n)*</th>
<th>HBV Recurrence (%)</th>
<th>Median Follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fung et al 23</td>
<td>80</td>
<td>No HBIG</td>
<td>ETV (80)</td>
<td>18/80 (23)</td>
<td>26</td>
</tr>
<tr>
<td>Wadhawan et al 45</td>
<td>75</td>
<td>No HBIG</td>
<td>LAM + ADV (19)</td>
<td>6/75 (8)</td>
<td>21</td>
</tr>
<tr>
<td>Degertekin et al 20</td>
<td>23</td>
<td>HBIG for 12 months</td>
<td>LAM</td>
<td>3/23 (13)</td>
<td>53</td>
</tr>
<tr>
<td>Nath et al 37</td>
<td>14</td>
<td>HBIG for 7 days</td>
<td>LAM + ADV</td>
<td>0/14 (0)</td>
<td>14</td>
</tr>
<tr>
<td>Teperman et al 39</td>
<td>16</td>
<td>HBIG for 6 months</td>
<td>FTC + TDF</td>
<td>0/16 (0)</td>
<td>18</td>
</tr>
<tr>
<td>Neff et al 42</td>
<td>10</td>
<td>HBIG for 7 months</td>
<td>LAM + ADV</td>
<td>0/10 (0)</td>
<td>31</td>
</tr>
</tbody>
</table>

*The specific number of patients on each oral regimen is unknown.

ADV, adefovir; ETV, entecavir; FTC, emtricitabine; HBIG, hepatitis B immunoglobulin; HBV, hepatitis B virus; LAM, lamivudine; TDF, tenofovir.
For example, at the University of California, Los Angeles, the combination of HBIG and an oral antiviral therapy is used for the first 12 months after transplantation. After this time, a second agent is introduced, and the HBIG is discontinued.40 This therapy has not only been shown to have similar efficacy to that of HBIG, but the cost benefit also makes the discontinuation of HBIG attractive (Table 3). Although further study with larger populations and longer follow-up periods needs to be conducted for a more standardized posttransplant protocol, the current results appear to be an encouraging step in the right direction.

The favorable results for the discontinuation of therapy with HBIG after a finite period of time have raised the question of whether the potency of the newer NA medications has superseded the need for HBIG. A study by Fung and colleagues tried to answer this question.23 In this study, patients were given entecavir in the posttransplant period without any HBIG and underwent follow-up for a mean period of 26 months. The results of the study were that HBV infection recurred in 18 (22.5%) of the 80 patients followed. Somewhat in contradiction to the previous study, Wadhawan and colleagues released a report in which they prospectively followed a cohort of 75 patients in which varying single and dual combinations of NAs were used for prophylaxis instead of HBIG between the years of 2005 and 2012, with encouraging results.45 Recurrence of HBV infection while on therapy was diagnosed in only 6 (8%) of the 75 patients. To be fair, the cohort of 75 patients was deemed to be at low risk for HBV recurrence, evidenced by HBV DNA negativity prior to transplantation. The recent improved results of patients with only combination or singular oral therapy mean that the role of HBIG in the posttransplant setting must be reevaluated to adapt to the changing therapies that are available.

### Management of Recurrence

The choice of therapy depends on the prophylactic therapy that the patient was receiving. This is, in part, due to the unfortunate fact that resistance can develop to several of the currently available medications, as seen with lamivudine or adefovir. Generally, if patients are on both HBIG and an oral agent, resistance is likely against HBIG, and the addition of complementary oral agents generally is effective in achieving viral suppression. If patients were taking a nucleoside analogue, then a nucleotide analogue should be added. For instance, the results of a large study demonstrated that the use of adefovir in patients with lamivudine-resistant HBV infection was associated with 95% viral suppression.46

Resistance to adefovir also can develop in patients who were treated with adefovir pretransplantation, and this resistance can carry over into the posttransplantation period.47-50 In the pretransplant setting, studies have indicated that lamivudine and entecavir are potent options in the setting of adefovir resistance.51 Although studies are lacking in the posttransplant phase, it is still prudent to add either lamivudine or entecavir to patients with known adefovir resistance.

### Conclusion

The use of prophylactic strategies has reduced the incidence of HBV infection recurrence in liver transplant recipients. Emerging data suggest that the use of HBIG may not necessarily be lifelong. Already, combination oral therapy is effective in treating recurrent HBV infection because of viral breakthrough during HBIG and lamivudine. In addition, the use of all-oral antiviral therapy has been shown to prevent recurrent infection after HBIG has been discontinued. The optimal period of using HBIG is not known, but it is used in most studies for at least 6 to 12 months. A controversial topic is whether HBIG is truly necessary for all patients who have undergone liver transplantation for management of HBV infection. Studies are required to see whether patients at low risk for recurrent infection can receive only all-oral combination therapy.

Dr Manne and Ms Allen have no relevant conflicts of interest to disclose. Dr Saab is a consultant and is on the speakers bureau for Gilead and Bristol-Myers Squibb.

### References

PREVENTION OF RECURRENT HBV INFECTION AFTER LIVER TRANSPLANTATION

3. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carci-

4. Brooks J, Gelson W, Rushbrook SM. Therapeutic advances in the manage-


11. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipi-
ents. J Viral Hepat. 2007;14(suppl 1):37-44.

12. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglob-
ulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011;17(10):1176-1190.


20. Marziano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplanta-


23. Yi NJ, Lee KW, Kong SY, et al. Outcome of various treatments for posttrans-


25. Sommers JS, Shaw T, Angus PW, et al. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for preven-


29. Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver trans-


31. Schiff E, Lai CL, Hadziyannis S, et al; Adefovir Dipivoxil Study 45 Interna-